Exhibit 16.1
June 25, 2021
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Ladies and Gentlemen:
We have read the statements made by Enveric Biosciences, Inc. under Item 4.01 of its Form 8-K filed on June 25, 2021. We agree with the statements concerning our Firm under Item 4.01; we are not in a position to agree or disagree with other statements contained therein.
Very truly yours,
/s/ Marcum LLP
Attachments
Disclaimer
Enveric Biosciences Inc. published this content on 28 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 June 2021 21:02:07 UTC.
